Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Julia Hoellenriegel"'
Autor:
Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify
Externí odkaz:
https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Autor:
Jan A. Burger, Dan A. Landau, Amaro Taylor-Weiner, Ivana Bozic, Huidan Zhang, Kristopher Sarosiek, Lili Wang, Chip Stewart, Jean Fan, Julia Hoellenriegel, Mariela Sivina, Adrian M. Dubuc, Cameron Fraser, Yulong Han, Shuqiang Li, Kenneth J. Livak, Lihua Zou, Youzhong Wan, Sergej Konoplev, Carrie Sougnez, Jennifer R. Brown, Lynne V. Abruzzo, Scott L. Carter, Michael J. Keating, Matthew S. Davids, William G. Wierda, Kristian Cibulskis, Thorsten Zenz, Lillian Werner, Paola Dal Cin, Peter Kharchencko, Donna Neuberg, Hagop Kantarjian, Eric Lander, Stacey Gabriel, Susan O’Brien, Anthony Letai, David A. Weitz, Martin A. Nowak, Gad Getz, Catherine J. Wu
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
The BTK inhibitor ibrutinib is used to treat chronic lymphocytic leukaemia, however some patients develop resistance to the drug. Here, the authors use genomic analyses to examine the clonal evolution of 5 patients that develop resistance to ibrutini
Externí odkaz:
https://doaj.org/article/31a1991cd4d64583af26755ec24a7d52
Autor:
Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, Zeev Estrov, Rossana Maffei, Susan O'Brien, Mariela Sivina, Julia Hoellenriegel, William G Wierda, Michael J Keating, Wei Ding, Neil E Kay, Brian J Lannutti, Roberto Marasca, Jan A Burger
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83830 (2013)
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior
Externí odkaz:
https://doaj.org/article/e562921b6e994148966ffc9a7ab695c4
Autor:
André Schmitz, Alexandra Schwarz, Michael Foss, Lixin Zhou, Birgit Rabe, Julia Hoellenriegel, Miriam Stoeber, Nelly Panté, Michael Kann
Publikováno v:
PLoS Pathogens, Vol 6, Iss 1, p e1000741 (2010)
Virtually all DNA viruses including hepatitis B viruses (HBV) replicate their genome inside the nucleus. In non-dividing cells, the genome has to pass through the nuclear pore complexes (NPCs) by the aid of nuclear transport receptors as e.g. importi
Externí odkaz:
https://doaj.org/article/f066420f2cb940798d0f0408a472e63b
Autor:
Wandi Zhang, Carrie Cibulskis, Joshua A Fein, Clare Sun, Sarangan Ravichandran, Catherine J. Wu, Jan A. Burger, Mohammed Farooqui, Mariela Sivina, Gad Getz, Sarah E. M. Herman, Adrian Wiestner, Ivana Bozic, Ignaty Leshchiner, Donna Neuberg, Dimitri Livitz, Daniel Rosebrock, Julia Hoellenriegel, Chingiz Underbayev, Asaf Zviran, Delong Liu, Dan A. Landau
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
Nature Communications
Nature Communications
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents. To define the evolutionary dynamics induced by targeted therapy in CLL, we perform serial exome and transcriptome sequencing for 61 ibrutinib-tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c25a3a546c862f7994cf69bb0e974d
https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Autor:
Anna Kruschinski, Michael J. Keating, William G. Wierda, Dirk Zboralski, Jan A. Burger, Nathalie Y. Rosin, Christian Maasch, Julia Hoellenriegel
Publikováno v:
Blood. 123:1032-1039
The CXC chemokine ligand (CXCL12, or stromal cell-derived factor-1 as previously known) plays a critical role for homing and retention of chronic lymphocytic leukemia (CLL) cells in tissues such as the bone marrow (BM). In tissues, stromal cells cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4935b6ec56f180b2bf829b1cb4274ab3
https://doi.org/10.1182/blood-2013-03-493924
https://doi.org/10.1182/blood-2013-03-493924
Autor:
Chip Stewart, Mariela Sivina, Yu Long Han, Kristian Cibulskis, Stacey Gabriel, Sergej Konoplev, Julia Hoellenriegel, David A. Weitz, Michael J. Keating, Amaro Taylor-Weiner, Cameron Fraser, Lillian Werner, Martin A. Nowak, Thorsten Zenz, Carrie Sougnez, Gad Getz, Jennifer R. Brown, Youzhong Wan, Donna Neuberg, Kristopher A. Sarosiek, Susan O'Brien, Huidan Zhang, Dan A. Landau, Jean Fan, Lili Wang, Hagop M. Kantarjian, William G. Wierda, Ivana Bozic, Anthony Letai, Jan A. Burger, Scott L. Carter, Peter Kharchencko, Lynne V. Abruzzo, Lihua Zou, Catherine J. Wu, Paola Dal Cin, Adrian M. Dubuc, Matthew S. Davids, Shuqiang Li, Kenneth J. Livak, Eric S. Lander
Publikováno v:
Nature communications, vol 7, iss 1
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Nature
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Nature
Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in seria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5a726afcf552a4d4639969d4bedcd3f
https://escholarship.org/uc/item/0p25f2hx
https://escholarship.org/uc/item/0p25f2hx
Autor:
Uma Sinha, Jan A. Burger, Mariela Sivina, Farhad Ravandi, William G. Wierda, Susan O'Brien, Michael J. Keating, Julia Hoellenriegel, Alessandra Ferrajoli, Anjali Pandey, Greg Coffey
Publikováno v:
Leukemia. 26:1576-1583
Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3d395221e506387bfe4a14e57826dcb
https://doi.org/10.1038/leu.2012.24
https://doi.org/10.1038/leu.2012.24
Autor:
Nathan Fowler, Wing C. Chan, Mariela Sivina, Xuelin Huang, Fredrick B. Hagemeister, Kai Fu, Koichi Takahashi, Richard E. Davis, Michael J. Keating, Julie M. Vose, Susan O'Brien, Yasuhiro Oki, Jorge E. Romaguera, Michelle A. Fanale, Felipe Samaniego, Larry W. Kwak, Julia Hoellenriegel, William G. Wierda, Luis Fayad, Sattva S. Neelapu, Lianchun Xiao, Hagop M. Kantarjian, Jan A. Burger
Publikováno v:
British journal of haematology, vol 171, iss 5
B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e22478e08bfc1f66e36c29ca2a5aff01
https://escholarship.org/uc/item/2gk5x6x7
https://escholarship.org/uc/item/2gk5x6x7
Autor:
Susan Lerner, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Julia Hoellenriegel, Xuelin Huang, Iris de Weerdt, Andreas Rosenwald, Graciela M. Nogueras-Gonzalez, Susan O'Brien, William G. Wierda, Michael J. Keating, Nathalie Y. Rosin, Ghayathri Jeyakumar, Elena Hartmann, Marylou Cardenas-Turanzas, Naveen Garg, Alessandra Ferrajoli, Gracy Zacharian, Jan A. Burger
Publikováno v:
The Lancet. Oncology, vol 15, iss 10
BackgroundIbrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7a57ec0345c1607764e89ce87212aa5
https://escholarship.org/uc/item/9nz3k8g7
https://escholarship.org/uc/item/9nz3k8g7